M&A Deal Summary |
|
|---|---|
| Date | 2020-06-15 |
| Target | Tocagen |
| Sector | Life Science |
| Buyer(s) | Forte Biosciences |
| Deal Type | Merger |
| Advisor(s) | Ladenburg Thalmann & Co. (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2007 |
| Sector | Life Science |
| Employees | 11 |
| Revenue | 32M USD (2023) |
Forte Biosciences is a clinical-stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric (3 years of age and older) patients with atopic dermatitis. Forte Biosciences was incorporated in 2007 and is based in Torrance, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |